NCT03691909View on ClinicalTrials.gov

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

August 17, 2020

Study Completion Date

September 28, 2020

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

HB-adMSCs

Hope Biosciences autologous adipose-derived mesenchymal stem cells

Trial Locations (1)

77034

Accurate Clinical Research, Pasadena

Sponsors
All Listed Sponsors
lead

Hope Biosciences LLC

INDUSTRY

NCT03691909 - Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter